DLD Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

DLD Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-38,436	Closed	-$3.74M	–	76
2023 Q1	$3.74M	Buy	38,436 +21,706	+130%	+$2.25M	0.31%	62
2022 Q4	$1.73M	Buy	16,730 +4,000	+31%	+$376K	0.15%	83
2022 Q3	$1.08M	Buy	12,730 +530	+4%	+$47.2K	0.08%	111
2022 Q2	$1.01M	Buy	+12,200	New	+$971K	0.07%	120
2021 Q2	–	Sell	-38,300	Closed	-$2.89M	–	149
2021 Q1	$2.89M	Buy	+38,300	New	+$3.13M	0.08%	81
2020 Q2	–	Sell	-23,720	Closed	-$2M	–	74
2020 Q1	$2M	Buy	23,720 +720	+3%	+$62K	0.13%	62
2019 Q4	$1.95M	Buy	23,000 +200	+0.9%	+$15.1K	0.1%	62
2019 Q3	$1.54M	Sell	22,800 -4,500	-16%	-$347K	0.08%	59
2019 Q2	$2.34M	Sell	27,300 -6,100	-18%	-$522K	0.1%	59
2019 Q1	$2.97M	Buy	33,400 +23,000	+221%	+$2.13M	0.11%	59
2018 Q4	$886K	Buy	+10,400	New	+$989K	0.06%	68

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DLD Asset Management's BMRN Position: Q2 2023 in Review

DLD Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 38,436 shares — an estimated $3.74M sold.

DLD Asset Management first reported a position in BMRN in Q4 2018 and held it in 11 quarters. The position peaked at $3.74M in Q1 2023. 557 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

DLD Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
DLD Asset Management sold 38,436 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $3.74M.
DLD Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 11 quarters.
DLD Asset Management's BioMarin Pharmaceuticals position peaked at $3.74M in Q1 2023.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on DLD Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.